Cytokinetics, Incorporated (NASDAQ:CYTK) Holdings Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 2.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 373,229 shares of the biopharmaceutical company's stock after selling 9,947 shares during the period. Nuveen Asset Management LLC owned approximately 0.32% of Cytokinetics worth $17,557,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Orbimed Advisors LLC raised its holdings in Cytokinetics by 106.5% in the fourth quarter. Orbimed Advisors LLC now owns 1,584,005 shares of the biopharmaceutical company's stock valued at $74,512,000 after buying an additional 817,099 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Cytokinetics by 0.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,658 shares of the biopharmaceutical company's stock valued at $3,372,000 after acquiring an additional 659 shares in the last quarter. Integral Health Asset Management LLC grew its position in Cytokinetics by 33.3% in the fourth quarter. Integral Health Asset Management LLC now owns 1,000,000 shares of the biopharmaceutical company's stock valued at $47,040,000 after acquiring an additional 250,000 shares in the last quarter. Hudson Bay Capital Management LP grew its position in Cytokinetics by 109.3% in the fourth quarter. Hudson Bay Capital Management LP now owns 141,269 shares of the biopharmaceutical company's stock valued at $6,645,000 after acquiring an additional 73,769 shares in the last quarter. Finally, Deep Track Capital LP grew its position in Cytokinetics by 296.9% in the fourth quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company's stock valued at $117,600,000 after acquiring an additional 1,870,094 shares in the last quarter.

Insider Transactions at Cytokinetics

In other news, EVP Andrew Callos sold 3,341 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares in the company, valued at approximately $2,788,059.18. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Muna Bhanji sold 1,454 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $29.73, for a total transaction of $43,227.42. Following the transaction, the director now owns 23,510 shares of the company's stock, valued at $698,952.30. This represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,816 shares of company stock worth $3,850,385. Insiders own 2.70% of the company's stock.

Cytokinetics Stock Performance

Cytokinetics stock traded down $0.01 during mid-day trading on Tuesday, reaching $30.53. The company's stock had a trading volume of 1,887,989 shares, compared to its average volume of 1,621,552. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of -5.67 and a beta of 0.81. The business has a 50 day moving average price of $37.32 and a 200-day moving average price of $44.22. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $61.38.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.05. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.77 million. The business's revenue was up 89.1% compared to the same quarter last year. During the same period last year, the firm posted ($1.33) EPS. Sell-side analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CYTK. Bank of America lowered their price objective on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating for the company in a research report on Tuesday, April 15th. Citigroup lowered their price objective on shares of Cytokinetics from $86.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Barclays lowered their price objective on shares of Cytokinetics from $55.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research report on Monday, April 21st. Finally, UBS Group lowered their price objective on shares of Cytokinetics from $47.00 to $41.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $74.73.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.